293 related articles for article (PubMed ID: 4197759)
1. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
Christiani K; Möller WD
Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
[No Abstract] [Full Text] [Related]
2. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
Lombardo L; de la Garza R; Ivan-Reynoso G
Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
[No Abstract] [Full Text] [Related]
3. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
[No Abstract] [Full Text] [Related]
4. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
[No Abstract] [Full Text] [Related]
5. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; de Ajuriaguerra J
Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
[No Abstract] [Full Text] [Related]
6. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
Wälzholz U; Schönfelder H
Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
[No Abstract] [Full Text] [Related]
7. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Steinhäusl H
Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
[No Abstract] [Full Text] [Related]
8. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
Klawans HL; Ringel SP
Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
[No Abstract] [Full Text] [Related]
9. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
Feise G; Paal G
Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
[No Abstract] [Full Text] [Related]
10. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
11. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
[No Abstract] [Full Text] [Related]
12. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
13. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
Görlich J; Markus E
Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
[No Abstract] [Full Text] [Related]
14. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
15. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
[No Abstract] [Full Text] [Related]
16. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
[No Abstract] [Full Text] [Related]
17. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
Gattringer B; Steinhäusl H
Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
[No Abstract] [Full Text] [Related]
18. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
[No Abstract] [Full Text] [Related]
19. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
Barbeau A; Mars H; Botez MI; Joubert M
Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
Ferel D
Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
[No Abstract] [Full Text] [Related]
[Next] [New Search]
